Jpmorgan Chase & CO Hutchmed (China) LTD Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding HCM
# of Institutions
66Shares Held
8.25MCall Options Held
3.8KPut Options Held
2.4K-
Schroder Investment Management Group London, X03.02MShares$54.4 Million0.06% of portfolio
-
Allianz Asset Management Gmb H Munich, 2M1.5MShares$27 Million0.04% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.15MShares$20.7 Million0.33% of portfolio
-
Acadian Asset Management LLC Boston, MA389KShares$7 Million0.02% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny358KShares$6.44 Million0.0% of portfolio
About HUTCHMED (China) Ltd
- Ticker HCM
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 172,955,008
- Market Cap $3.11B
- Description
- HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...